Bonesupport

CONTINUED STRONG GROWTH IN BOTH SEGMENTS

JULY – SEPTEMBER 2023

• Net sales increased by 87 percent (76 percent at constant exchange rates) and amounted to SEK 158.2 million (84.6).
• The North America (NA) segment reported a sales growth of 115 percent (102 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (26 percent at constant exchange rates).
• The gross margin amounted to 92.1 percent (90.8).
• The operating result before effects from the Group’s incentive programs amounted to SEK +24.6 million (-4.4). Reported operating result amounted to SEK +14.9 million (-13.9).
• Earnings per share before dilution were SEK +3.52 (-0.23). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share before dilution were SEK +0.18.
• Earnings per share after dilution were SEK +3.47 (-0.23). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share after dilution were SEK +0.18.

JANUARY – SEPTEMBER 2023

• Net sales increased by 85 percent (75 percent at constant exchange rates) and amounted to SEK 418.3 million (225.6).
• The North America (NA) segment reported a sales growth of 117 percent (103 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (26 percent at constant exchange rates).
• The gross margin amounted to 91.4 percent (90.1)
• The operating result before effects from the Group’s incentive programs amounted to SEK +42.8 million (-26.1). Reported operating result amounted to SEK +21.6 million (-45.3).
• Earnings per share before dilution were SEK +3.61 (-0.74). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share before dilution were SEK +0.26.
• Earnings per share after dilution were SEK +3.56 (-0.74). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share after dilution were SEK +0.26.

"87 percent sales growth and the first quarter with positive cash flow." Emil Billbäck, CEO

EVENTS DURING THE REPORTING PERIOD

• During August, the last patient was enrolled to the SOLARIO study.
• During the quarter, the Company recognized deferred tax receivables on its tax losses carried forward in the balance sheet for the first time, amounting to SEK 230 million.

EVENTS AFTER THE REPORTING PERIOD
In October 2023, BONESUPPORT received Breakthrough device designation from the FDA for CERAMENT V for the indication of bone infection.